eptinezumabgalcanezumabfremenezumabonabotulinumtoxinAPharmaceutical Benefits Schemechronic migraine
…remenezumab and galcanezumab. Conclusion Our findings show that eptinezumab is a safe, well-tolerated migraine prophylactic that decreases …
8articles mentioning drugs
25drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Eptinezumab ×
Eptinezumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Eptinezumab
8 articles · page 1 of 1eptinezumabnational health systemCMMMDbotulinum toxinHFEMchronic migraine
…(≥15 MMD) or HFEM (10-15 MMD) who received at least one dose of eptinezumab at our hospital between April 24 and June 25.The following data…
galcanezumabfremanezumaberenumabeptinezumabrimegepantatogepant
…9% male; 64.6% received fremanezumab, 24.8% erenumab, 10.6% and galcanezumab; 75.7% were on first-line therapy, 21.7% second-line and 2.7% t…
galcanezumabfremanezumabRimegepanteptinezumaberenumab
…epant: 5 changed from erenumab, 2 from galcanezumab, and 1 from galcanezumab. There were 11 line changes to eptinezumab: 5 from erenumab, 4 …
eptinezumabgalcanezumaberenumabmigraineanti-CGRP therapies
…frequent for erenumab (31%), followed by galcanezumab (27%) and eptinezumab (15%).Conclusion and Relevance Treatment effectiveness was obse…
eptinezumabgalcanezumaberenumabfremanezumabtertiary hospitalchronic or episodic migrainechronic migraine
…mab, 44.4% (55) fremanezumab, 15.3% (19) erenumab, and 2.4% (3) eptinezumab.First cycle efficacy: The median baseline MMD was 12 (10–15.5),…
galcanezumaberenumabeptinezumabatogepantfremanezumabmigrainepreventive therapies
…he following CGRP pathway-targeted preventive treatments: 32.4% galcanezumab, 28.1% erenumab, 24.3% fremanezumab, 8.2% atogepant, 2.5% eptin…
propranololpropranolol hydrochloriderimegepantRAMP1CALCRLfremanezumaberenumabgalcanezumabCGRP
…ated lesions after denervation in rats.50 β-blockers (including propranolol and propranolol hydrochloride), which target adrenergic nerves,…